News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Catalent Pharma Solutions Expert Will Present at the "Drug Development Decisions: the NDA Simulation Workshop" for the Pharmaceutical Education and Research Institute (PERI)


7/18/2012 9:58:35 AM

SOMERSET, NJ, July 18, 2012 – Carolyn Finkle, Vice President, Global Regulatory Consulting at Catalent Pharma Solutions will present “Chemistry, Manufacturing and Control” for a course entitled “Drug Development Decisions: The NDA Simulation Workshop” for the Pharmaceutical Education and Research Institute (PERI) on July 23, 2012 at the PERI training facility in Arlington, VA.

This course addresses the global aspects of drug development. In this highly interactive course participants will gain a better understanding of the overall drug development and regulatory processes by participating in a simulated drug development and review process. Presentations made by real-world functional area experts provide the groundwork for the IND and NDA Game simulations.

Ms. Finkle leads the Global Regulatory Consulting Services for Catalent, which provides comprehensive consulting services, developing and implementing solutions to enhance clients’ performance in pharmaceutical and biotechnology research and development. Catalent has a team of experienced regulatory affairs professionals who can provide regulatory support at early and late stage product development, from Pre-IND FDA meeting support and IND/IMPD/CTA filings to Pre-NDA/BLA/MAA support and managing NDA/BLA/MAA submissions. Catalent’s unique approach is a combination of strategic and tactical consulting and practical, hands-on implementation to improve the speed, efficiency and quality of the entire product development process.

Ms. Finkle has more than 25 years of scientific and industry experience including 15 years in management of drug and biologic development, quality and regulatory affairs for companies in the U.S. and Canada. Before joining Catalent, Ms. Finkle worked with MedImmune/AZ, PAREXEL International, Celsion Corporation, TherImmune Research Corporation, GeminX Biotechnologies, ConjuChem and BioChem Pharma. She has received numerous awards and scholarships throughout her career and currently serves as a faculty member of the PERI and adhoc faculty for the University of California San Francisco (UCSF) American Course of Drug Development and Regulatory Sciences (ACDRS). Ms. Finkle has also co-authored one book chapter, more than 18 abstracts and 12 papers for industry associations and scientific publications.

For more information on this course and to register, please visit

https://netforum.avectra.com/eweb/DynamicPage.aspx?Site=PERI&WebCode=EventLocation&evt_key=42173e84-b88b-48df-8dee-eaabf901ff3c.

About Catalent

From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs approximately 9,400 people at 29 facilities worldwide and in fiscal year 2011 generated more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, NJ. For more information, visit www.catalent.com.

more products. better treatments. reliably supplied.™

Media Contact:

Patricia McGee

T +1 (732) 537 6407

patricia.mcgee@catalent.com


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES